Abstract：
Myasthenia gravis is an autoimmune disorder characterized by the presence of autoantibodies against the acetylcholine receptor present in the post-synaptic membrane of the neuromuscular junction impairing the muscle contraction and causing the patient suffering from the disorder to develop a myriad of muscular defects ranging from drooping of eyelids, blurred or double vision, shortness of breath, difficulty in swallowing, as well as weakness of limbs and arms. Myasthenia gravis is known as the disease of old men and young women but in contrast to the global scenario, in India, myasthenia gravis was found to be predominant in males with the ratio of 2.70:1. Though the disorder has been studied for centuries, the true reason for disease and its pathophysiology still eludes us. But recent advancement in molecular biology and diagnostic tools has enabled us to identify many targets for pharmacotherapy as well as for early diagnosis. Thus, improving the patient\'s morbidity and quality of life. In this article, we are discussing the recent advancements made in diagnosis and therapy of the disease.
摘要：
重症肌无力是一种自身免疫性疾病，其特征是存在针对神经肌肉接头突触后膜中乙酰胆碱受体的自身抗体，损害肌肉收缩，并导致患有该疾病的患者出现无数的肌肉缺陷，包括眼睑下垂，模糊或复视，呼吸急促,吞咽困难,以及四肢和手臂的虚弱。重症肌无力被称为老年男性和年轻女性的疾病，但与全球情况相反，在印度,发现重症肌无力在男性中以2.70：1的比例占主导地位。尽管这种疾病已经研究了几个世纪，疾病的真正原因及其病理生理学仍然困扰着我们。但是分子生物学和诊断工具的最新进展使我们能够确定许多药物治疗和早期诊断的目标。因此，提高患者的发病率和生活质量。在这篇文章中,我们正在讨论该疾病的诊断和治疗方面的最新进展。
